Brief: Pharnext presents positive exploratory Phase 2 data from clinical trials on Alzheimer
13/12/2016 07:02
Dec 13 (Reuters) - Pharnext SAS PHARN.PA :
* Presents positive exploratory Phase 2 data from PXT864 at 9th clinical trials on
Alzheimer's disease (CTAD) conference in San Diego, United States
* Trial also confirmed excellent safety and tolerability of PXT864 over 36 weeks of
treatment
* Data from Phase 2 trial suggest promising efficacy of PXT864 in mild Alzheimer`s disease
Source text for Eikon: ID:nBw6FdNbka
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development